# Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

> **NCT01273662** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 45 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** AG-013736

## Key facts

- **NCT ID:** NCT01273662
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2016-03
- **Final completion:** 2016-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273662, "Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01273662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*